Lancet Diabetes Endo:大庆研究30年随访数据公布:对于糖代谢异常者,仅改变生活方式就能降低死亡风险

2019-05-03 xujing 中国循环杂志

近期,Lancet子刊在线发表了阜外医院内分泌和心血管病中心主任、中日友好医院内分泌首席专家李光伟教授研究团队的大庆研究30年随访结果。

近期,Lancet子刊在线发表了阜外医院内分泌和血管病中心主任、中日友好医院内分泌首席专家李光伟教授研究团队的大庆研究30年随访结果。

研究显示,6年的生活方式干预可使糖耐量受损人群的糖尿病发病延迟近4年,同时降低了血管事件、微血管并发症、心血管和全因死亡率的发生率,并延长了预期寿命。

研究始于1986年,共入选576例糖耐量受损患者,其中438例患者接受饮食和/或运动的生活方式干预(干预组)。

经过6年积极生活方式干预之后,对受试者进行长达30年的随访,576名受试者中有540名(94%)接受了效果评估(对照组135例,干预组405例)。

与没有接受生活方式干预的人相比,生活方式干预使糖耐量受损人群的糖尿病发病时间延迟3.96年。

同时,生活方式干预使糖尿病发生风险降低39%,心血管事件发生风险降低26%,复合严重微血管病变发生率降低35%,心血管疾病死亡率降低33%,全因死亡率降低26%;平均预期寿命增加1.44年。



图 累积糖尿病发病率降低39%



图 心血管事件发生风险降低26%



图 复合严重微血管病变发生率降低35%



图 全因死亡率降低26%

主要研究者李光伟教授表示,我们有更多理由扩大糖尿病预防的规模。如果能成功地在社区层面实现这种干预,将会大幅度降低日益增长的糖尿病及其不良心血管结局的医疗费用。

对于该研究,李光伟教授说,这是一项没有高科技的研究,高度使命感、信念坚定、甘于奉献的团队、坚实的国际合作都是研究成功的必备条件。

他也说,该研究最重要的经验是要找到科学性和可行性的恰当结合点,只有中等强度的干预才能被繁忙的大众接受并坚持。同时,小组而非个体教育最有效、最省钱。长期坚持也需要人们形成习惯。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1650673, encodeId=17a616506e3ce, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sat Jun 29 15:53:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902245, encodeId=d4b81902245b7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Feb 18 03:53:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830059, encodeId=ae43183005938, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 04 03:53:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761096, encodeId=c8bc1e61096a0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Mar 01 22:53:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639088, encodeId=0d781639088b5, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu May 23 10:53:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255849, encodeId=3cfa1255849b0, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360614, encodeId=2a7e136061404, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631798, encodeId=fecc1631e9813, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365676, encodeId=bd423656e6a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri May 03 21:28:31 CST 2019, time=2019-05-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1650673, encodeId=17a616506e3ce, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sat Jun 29 15:53:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902245, encodeId=d4b81902245b7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Feb 18 03:53:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830059, encodeId=ae43183005938, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 04 03:53:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761096, encodeId=c8bc1e61096a0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Mar 01 22:53:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639088, encodeId=0d781639088b5, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu May 23 10:53:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255849, encodeId=3cfa1255849b0, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360614, encodeId=2a7e136061404, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631798, encodeId=fecc1631e9813, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365676, encodeId=bd423656e6a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri May 03 21:28:31 CST 2019, time=2019-05-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1650673, encodeId=17a616506e3ce, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sat Jun 29 15:53:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902245, encodeId=d4b81902245b7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Feb 18 03:53:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830059, encodeId=ae43183005938, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 04 03:53:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761096, encodeId=c8bc1e61096a0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Mar 01 22:53:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639088, encodeId=0d781639088b5, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu May 23 10:53:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255849, encodeId=3cfa1255849b0, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360614, encodeId=2a7e136061404, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631798, encodeId=fecc1631e9813, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365676, encodeId=bd423656e6a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri May 03 21:28:31 CST 2019, time=2019-05-03, status=1, ipAttribution=)]
    2019-05-04 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1650673, encodeId=17a616506e3ce, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sat Jun 29 15:53:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902245, encodeId=d4b81902245b7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Feb 18 03:53:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830059, encodeId=ae43183005938, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 04 03:53:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761096, encodeId=c8bc1e61096a0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Mar 01 22:53:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639088, encodeId=0d781639088b5, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu May 23 10:53:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255849, encodeId=3cfa1255849b0, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360614, encodeId=2a7e136061404, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631798, encodeId=fecc1631e9813, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365676, encodeId=bd423656e6a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri May 03 21:28:31 CST 2019, time=2019-05-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1650673, encodeId=17a616506e3ce, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sat Jun 29 15:53:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902245, encodeId=d4b81902245b7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Feb 18 03:53:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830059, encodeId=ae43183005938, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 04 03:53:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761096, encodeId=c8bc1e61096a0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Mar 01 22:53:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639088, encodeId=0d781639088b5, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu May 23 10:53:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255849, encodeId=3cfa1255849b0, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360614, encodeId=2a7e136061404, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631798, encodeId=fecc1631e9813, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365676, encodeId=bd423656e6a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri May 03 21:28:31 CST 2019, time=2019-05-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1650673, encodeId=17a616506e3ce, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sat Jun 29 15:53:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902245, encodeId=d4b81902245b7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Feb 18 03:53:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830059, encodeId=ae43183005938, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 04 03:53:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761096, encodeId=c8bc1e61096a0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Mar 01 22:53:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639088, encodeId=0d781639088b5, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu May 23 10:53:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255849, encodeId=3cfa1255849b0, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360614, encodeId=2a7e136061404, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631798, encodeId=fecc1631e9813, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365676, encodeId=bd423656e6a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri May 03 21:28:31 CST 2019, time=2019-05-03, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1650673, encodeId=17a616506e3ce, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sat Jun 29 15:53:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902245, encodeId=d4b81902245b7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Feb 18 03:53:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830059, encodeId=ae43183005938, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 04 03:53:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761096, encodeId=c8bc1e61096a0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Mar 01 22:53:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639088, encodeId=0d781639088b5, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu May 23 10:53:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255849, encodeId=3cfa1255849b0, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360614, encodeId=2a7e136061404, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631798, encodeId=fecc1631e9813, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365676, encodeId=bd423656e6a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri May 03 21:28:31 CST 2019, time=2019-05-03, status=1, ipAttribution=)]
    2019-05-05 zz70
  8. [GetPortalCommentsPageByObjectIdResponse(id=1650673, encodeId=17a616506e3ce, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sat Jun 29 15:53:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902245, encodeId=d4b81902245b7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Feb 18 03:53:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830059, encodeId=ae43183005938, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 04 03:53:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761096, encodeId=c8bc1e61096a0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Mar 01 22:53:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639088, encodeId=0d781639088b5, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu May 23 10:53:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255849, encodeId=3cfa1255849b0, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360614, encodeId=2a7e136061404, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631798, encodeId=fecc1631e9813, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365676, encodeId=bd423656e6a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri May 03 21:28:31 CST 2019, time=2019-05-03, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1650673, encodeId=17a616506e3ce, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sat Jun 29 15:53:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902245, encodeId=d4b81902245b7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Feb 18 03:53:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830059, encodeId=ae43183005938, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 04 03:53:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761096, encodeId=c8bc1e61096a0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Mar 01 22:53:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639088, encodeId=0d781639088b5, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu May 23 10:53:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255849, encodeId=3cfa1255849b0, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360614, encodeId=2a7e136061404, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631798, encodeId=fecc1631e9813, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Sun May 05 10:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365676, encodeId=bd423656e6a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri May 03 21:28:31 CST 2019, time=2019-05-03, status=1, ipAttribution=)]
    2019-05-03 医者仁心5538

    学习了

    0

相关资讯

CSE 2015:MedSci专访李光伟教授——会做科研的医生才能登顶

2015年8月27日,在中国医学会第十四次全国内分泌学学术会议上,MedSci采访了中国医学科学院阜外心血管病医院内分泌与心血管病诊治中心主任--李光伟教授。李教授参与和主持的"大庆糖耐量低减(IGT)和糖尿病研究"、"大庆糖尿病预防20年跟踪研究"与美国及芬兰同类糖尿病预防一起被誉为世界2型糖尿病的一级预防里程碑式的研究。MedSci:对于临床医生要不要做科研,许多医生有不同的看法。李教授,

改变糖尿病防治的大庆研究

左三胡英华院长 左四Peter Bennett 左五潘孝仁主任 右一 李光伟主任 今年4月,“大庆糖尿病预防研究”23年随访结果发表在《柳叶刀·糖尿病与内分泌学》杂志上,这一研究结果被英国剑桥大学韦勒姆教授誉为“一个真正的突破”。 从1986年到今天,大庆研究已经持续了23年,先后三次发布的研究结果均轰动世界,在世界糖尿病研究的历史上具有里程碑式的意义,只要提到糖尿病的预防,大

李光伟团队在ADA报告大庆研究23年随访新发现:甘油三酯每增加一个单位,国人心血管病风险增加 8%

大庆研究23年随访研究的一项新发现,甘油三酯每增加一个单位,主要 CVD 的风险增加 8%。

CDS2018:大庆糖尿病预防30年随访研究揭示生活方式干预降低中国成人IGT患者死亡率

作为全球糖尿病预防领域的里程碑式研究,大庆糖尿病预防研究取得了累累硕果。2018年11月30日,在中华医学会糖尿病学分会第二十二次全国学术会议(CDS2018)的“糖尿病流行病学、卫生经济学及转化医学”专题上,中国医学科学院阜外医院巩秋红教授报告了大庆糖尿病预防30年随访研究结果,揭示了生活方式干预可降低中国成人糖耐量异常(IGT)患者的死亡率。

Diabetes Care:CVD占糖尿病患者死因半壁江山(大庆研究23年随访结果)

北京阜外医院李光伟教授团队的最新研究表明,糖尿病与中国成人死亡率增加相关, CVD是主要死因,其中卒中引起的死亡几乎占半数。文章4月17日在线发表于《糖尿病护理》(Diabetes Care)杂志。研究者对比了1986年大庆研究中从110 660例受试者中筛选出来的新诊断为糖尿病者(NDD,630例)与正常糖耐量者(NGT,519例)的死亡率和死因,受试者年龄为25~74岁。结果显示,2